Minhai COVID-19 vaccine

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Vaccine against COVID-19

Minhai COVID-19 vaccine
Vaccine description
Target SARS-CoV-2
Vaccine type Inactivated
Clinical data
Other names KCONVAC (Chinese:可维克; pinyin:Kěwéikè)
Routes of
administration
Intramuscular
Legal status
Legal status
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each “ball” is an atom.
 COVID-19 portal

. . . Minhai COVID-19 vaccine . . .

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1]

Later, KCONVAC started phase II trials with 1,000 participants in China.[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]

In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]

In September, KCONVAC started phase II trials with 480 participants in China.[5]

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]

. . . Minhai COVID-19 vaccine . . .

This article is issued from web site Wikipedia. The original article may be a bit shortened or modified. Some links may have been modified. The text is licensed under “Creative Commons – Attribution – Sharealike” [1] and some of the text can also be licensed under the terms of the “GNU Free Documentation License” [2]. Additional terms may apply for the media files. By using this site, you agree to our Legal pages . Web links: [1] [2]

. . . Minhai COVID-19 vaccine . . .